Literature DB >> 21087690

Evaluation of three recombinant multi-antigenic vaccines composed of surface and secretory antigens of Toxoplasma gondii in murine models of experimental toxoplasmosis.

Bozena Dziadek1, Justyna Gatkowska, Anna Brzostek, Jaroslaw Dziadek, Katarzyna Dzitko, Marcin Grzybowski, Henryka Dlugonska.   

Abstract

The great clinical and economical impact of Toxoplasma gondii infections makes the development of an effective vaccine for controlling toxoplasmosis an extremely important aim. In the presented study, we evaluate the protective and immunogenic properties of three recombinant subunit vaccines composed of rROP2+rGRA4+rSAG1, rROP2+rROP4+rGRA4 and rROP2+rROP4+rSAG1 proteins of T. gondii in an experimental toxoplasmosis model in the C3H/HeJ and C57BL/6 mouse strains. All three recombinant vaccines induced partial protection as measured by the reduction of brain cyst burden following challenge with five tissue cysts of the low virulence DX T. gondii strain. The level of protection was dependent on the antigen composition of the vaccine and the genetic background of the laboratory animals. The strongest protection against chronic toxoplasmosis was induced in both C3H/HeJ and C57BL/6 mice by the mixture of rhoptry proteins rROP2 and rROP4 combined with tachyzoite major protein rSAG1. The average parasite burden in these groups of mice was reduced by 71% and 90%, respectively, compared to non-vaccinated mice. The observed protective effect was related to the vaccine-induced cellular and humoral immune responses, as measured by the antigen-induced release of the Th1 cytokines IFN-γ and IL-2, the antigen-stimulated proliferation of spleen cells of vaccinated animals in comparison to control animals and the development of systemic antigen-specific IgG1 and IgG2a (C3H/HeJ) or IgG2c (C57BL/6) antibodies. Our studies show that recombinant rROP2, rROP4, rGRA4 and rSAG1 antigens may be promising candidates for a subunit vaccine against toxoplasmosis. Additionally, we demonstrate that the ideal composition of vaccine antigens can be equally effective in mice with different genetic backgrounds and variable levels of innate resistance to toxoplasmosis, resulting in strong protection against T. gondii invasion.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21087690     DOI: 10.1016/j.vaccine.2010.11.002

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

1.  Recombinant ROP2, ROP4, GRA4 and SAG1 antigen-cocktails as possible tools for immunoprophylaxis of toxoplasmosis: what's next?

Authors:  Bozena Dziadek; Anna Brzostek
Journal:  Bioengineered       Date:  2012-08-15       Impact factor: 3.269

Review 2.  PLGA Nanoparticles as an Efficient Platform in Protein Vaccines Against Toxoplasma gondii.

Authors:  Mojgan Allahyari
Journal:  Acta Parasitol       Date:  2022-01-11       Impact factor: 1.440

3.  Interleukin-10 Serum Levels after Vaccination with In Vivo Prepared Toxoplasma gondii Excreted/Secreted Antigens.

Authors:  Seyed Hossein Abdollahi; Fateme Ayoobi; Hossein Khorramdelazad; Gholamhossein Hassanshahi; Behzad Nasiri Ahmadabadi; Mohammadtaghi Rezayati; Ali Ravary; Ali Shamsizadeh; Mohammad Kazemi Arababadi
Journal:  Oman Med J       Date:  2013-03

4.  Towards vaccine against toxoplasmosis: evaluation of the immunogenic and protective activity of recombinant ROP5 and ROP18 Toxoplasma gondii proteins.

Authors:  Marcin M Grzybowski; Bożena Dziadek; Justyna M Gatkowska; Katarzyna Dzitko; Henryka Długońska
Journal:  Parasitol Res       Date:  2015-09-04       Impact factor: 2.289

5.  Levels of Transforming Growth Factor-Beta After Immunization of Mice With in vivo prepared Toxoplasma gondii Excretory/Secretory Proteins.

Authors:  Seyed Hossein Abdollahi; Fateme Ayoobi; Hossein Khorramdelazad; Behzad Nasiri Ahmadabadi; Mohammadtaghi Rezayati; Mohammad Kazemi Arababadi; Mohammad Zare-Bidaki
Journal:  Jundishapur J Microbiol       Date:  2015-05-31       Impact factor: 0.747

6.  Prime-boost vaccination with toxoplasma lysate antigen, but not with a mixture of recombinant protein antigens, leads to reduction of brain cyst formation in BALB/c mice.

Authors:  Angelika Wagner; Irma Schabussova; Bärbel Ruttkowski; Roman Peschke; Józef Kur; Michael Kundi; Anja Joachim; Ursula Wiedermann
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

7.  Intranasal immunisation with recombinant Toxoplasma gondii actin partly protects mice against toxoplasmosis.

Authors:  Li-Tian Yin; Hai-Xia Hao; Hai-Long Wang; Jian-Hong Zhang; Xiao-Li Meng; Guo-Rong Yin
Journal:  PLoS One       Date:  2013-12-27       Impact factor: 3.240

8.  Partial protective effect of intranasal immunization with recombinant Toxoplasma gondii rhoptry protein 17 against toxoplasmosis in mice.

Authors:  Hai-Long Wang; Tie-E Zhang; Li-Tian Yin; Min Pang; Li Guan; Hong-Li Liu; Jian-Hong Zhang; Xiao-Li Meng; Ji-Zhong Bai; Guo-Ping Zheng; Guo-Rong Yin
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

9.  An avian influenza A (H7N9) virus vaccine candidate based on the fusion protein of hemagglutinin globular head and Salmonella typhimurium flagellin.

Authors:  Li Song; Dan Xiong; Xilong Kang; Yun Yang; Jing Wang; Yaxin Guo; Hui Xu; Sujuan Chen; Daxin Peng; Zhiming Pan; Xinan Jiao
Journal:  BMC Biotechnol       Date:  2015-08-19       Impact factor: 2.563

10.  Toxoplasma gondii protein disulfide isomerase (TgPDI) is a novel vaccine candidate against toxoplasmosis.

Authors:  Hai-Long Wang; Ya-Qing Li; Li-Tian Yin; Xiao-Li Meng; Min Guo; Jian-Hong Zhang; Hong-Li Liu; Juan-Juan Liu; Guo-Rong Yin
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.